Wegovy is a once-weekly injection — here's what that actually means in practice

Picture week one: you have your pen, you've picked a day, and you're wondering whether once a week is really enough

That question comes up almost every time someone starts. The short answer is yes, by design. Semaglutide was engineered with a half-life close to seven days, which is unusually long for a peptide medicine. A single injection on, say, a Tuesday reaches peak levels in your bloodstream within one to three days, then declines slowly enough that by the following Tuesday meaningful concentrations are still present. The NHS semaglutide medicine guide confirms this once-weekly schedule as the standard licensed regimen.

The practical upside is consistency without daily complexity. Many people tie the injection to something fixed (first thing before Saturday breakfast, or Sunday evening) so it becomes unremarkable within a few weeks. If you want to understand why semaglutide is dosed on a weekly rather than daily basis, the pharmacology behind it is worth a quick read before you settle into your routine. That thirty-second habit catches the rare occasions you've lost count.

One detail worth knowing: if you miss an injection and it has been fewer than five days since your usual day, you can take it when you remember. Beyond that, skip it and resume on your next scheduled day. The prescriber and patient information leaflet are the authority on missed-dose decisions, not advice from forums or a friend who takes the same medicine at a different dose.

How the dose changes over the months, and what 'titration' means for the weekly rhythm

The weekly injection stays weekly throughout; what changes is the dose inside each pen. Wegovy's licensed pathway steps up approximately every four weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg as the standard maintenance dose. Slow escalation is the point, it gives the gut time to adapt and reduces the likelihood of nausea being severe enough to stop treatment. Our full Wegovy overview covers how each step of the schedule relates to side-effect management and the expected timeline to therapeutic effect.

In January 2026, the MHRA also approved 7.2 mg as a higher maintenance option for eligible adults, delivered, initially, across three 2.4 mg pens per week, with a dedicated single-dose 7.2 mg pen approved in April 2026. Whether that dose is appropriate for any individual patient is a clinical decision, not one to take from a webpage. If you have questions about whether Wegovy is always taken on a weekly basis, including how that applies across different dose levels, that page explains it clearly.

NICE's appraisal of semaglutide for weight management, TA875 published March 2023, recommends it for eligible adults within specialist weight management services and sets a two-year treatment limit. Private prescribers work under the licensed terms, not NICE's NHS commissioning restrictions, but the same weekly schedule and clinical oversight apply.

Who the weekly injection is and isn't suitable for

Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone doesn't determine approval, a prescriber reviews the full picture, including other medicines you take, your medical history and any conditions that might make GLP-1 treatment unsuitable.

It is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, or certain gastrointestinal conditions, require a careful clinical conversation before any decision is made.

If you're wondering what the private route looks like (how access works, what the process involves and what to expect from a consultation) this page on getting Wegovy through a regulated UK pharmacy covers it clearly. For cost context, our treatment page sets out current pricing in full, without hidden fees.

Side effects tied to the weekly cycle, what's normal and when to act

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion and occasional vomiting. These tend to be most noticeable in the first week or two after a dose increase, then settle as the body adjusts. They are not random, they follow the weekly injection cycle, often peaking two to three days after each dose, which is why most clinicians suggest injecting on a day when you can take it easy the next morning if needed.

Rarer but serious: severe and persistent stomach pain that radiates toward the back, with or without vomiting, requires urgent medical attention as it may signal pancreatitis. The MHRA issued a Drug Safety Update on this in January 2026 covering GLP-1 medicines as a class. Any suspected side effect can be reported through the Yellow Card scheme, this applies to patients as well as healthcare professionals. Gallbladder symptoms, signs of a serious allergic reaction and anything that prompts real concern about your health should go to a doctor or 111, not to a pharmacy helpdesk.

Our FAQs page covers the questions our prescribers hear most often about managing side effects around the weekly schedule, including a dedicated section for anyone still asking whether Wegovy really is just once a week. And if something feels off between doses, our aftercare team is available seven days a week. If you'd like a prescriber to assess whether Wegovy is suitable for you, starting a free consultation is the next step.